Dr. Sara Hurvitz

0:15:30

Dr. Sara Hurvitz | San Antonio Breast Cancer Symposium 2022 | General Session

1:03:11

HR-Positive Breast Cancer — An Interview with Dr Sara A Hurvitz on the Role of Endocrine-Based Th...

0:00:35

Dr. Sara Hurvitz invites you the International Congress on the Future of Breast Cancer West

0:02:01

Dr. Hurvitz on HER2-Targeted Therapies in Breast Cancer

0:06:53

A discussion with Dr. Sara Hurvitz, San Antonio Breast Cancer Symposium 2010.

0:03:41

Patient Success Stories: Metastatic ER+ Breast Cancer, Sara Hurvitz MD

1:03:11

HR-Positive Breast Cancer — An Interview with Dr Sara A Hurvitz on the Role of Endocrine-Based Th...

0:01:03

Dr. Hurvitz on Steps to Take With HER2-Positive Breast Cancer Research

0:01:13

UCLA Jonsson Comprehensive Cancer Center is a Top Cancer Research & Treatment Center - Dr. Hurvitz

0:01:55

Dr. Hurvitz on the FDA Approval Process for Biosimilars

0:01:46

Dr. Hurvitz on Biosimilars in Breast Cancer

0:00:58

Dr. Hurvitz on Treatment Options for HER2-Positive Breast Cancer

0:02:15

Dr. Hurvitz on Neoadjuvant Therapy for HER2+ Breast Cancer

0:01:41

Dr. Hurvitz on Toxicity Associated With Neratinib in HER2+ Breast Cancer

0:08:10

ASCO 2012 preview: new melanoma therapies

0:03:34

Sara Hurvitz, MD, describes the recently reported results using PARP inhibition and cisplatin

0:03:12

Sara Hurvitz, MD, shares design and outcomes of the HER2CLIMB study in advanced breast cancer

0:01:29

Dr. Hurvitz on Standards of Care in HER2+ Breast Cancer

0:01:39

Dr. Hurvitz on the Lack of Predictive Biomarkers in HER2+ Breast Cancer

0:01:38

Dr. Hurvitz on the Impact of Biosimilars

0:23:31

SABCS 2021: The ideal partner to HER2 directed therapies

0:01:30

Patient Concerns and Treatment Decisions Are Impacted By Disease Stage

0:03:20

Dr. Hurvitz on Eliminating Anthracyclines in HER2+ Breast Cancer Treatment

0:05:17

Treatment Selection for HR+ mBC